Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial - PubMed
2 hours ago
- #statin intolerance
- #venous thromboembolism
- #bempedoic acid
- A post hoc analysis of the CLEAR Outcomes trial found that bempedoic acid reduces venous thromboembolism (VTE) risk in statin-intolerant patients.
- The randomized trial included 13,970 participants at high cardiovascular risk, comparing daily bempedoic acid (180 mg) versus placebo.
- Results showed a hazard ratio of 0.58 for VTE events, indicating a 42% lower risk with bempedoic acid compared to placebo.
- Both deep vein thrombosis and pulmonary embolism risks were significantly reduced, with hazard ratios of 0.56 and 0.61 respectively.
- The findings suggest bempedoic acid could be an alternative therapy for reducing VTE risk in statin-intolerant individuals.